Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.51 |
| ▸ | ACVR1 | Q04771 | 12/20 | 0.50 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.46 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.40 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.39 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.39 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29757784 | 1.00 | EGFR (0.51) | EGFRACVR1PTK2FGFR3BMPR1B | |
| SCHEMBL23759769 | 0.96 | EGFR (0.48) | EGFRACVR1PTK2FGFR3 | |
| SCHEMBL22950983 | 0.94 | EGFR (0.45) | EGFRACVR1PTK2 | |
| SCHEMBL22950934 | 0.93 | EGFR (0.45) | EGFRACVR1PTK2BMPR1A | |
| SCHEMBL24780434 | 0.91 | EGFR (0.44) | EGFRACVR1PTK2 | |
| SCHEMBL22950966 | 0.91 | EGFR (0.43) | EGFRACVR1PTK2BMPR1A | |
| SCHEMBL23442017 | 0.90 | MAPK8 (0.44) | EGFRACVR1 | |
| SCHEMBL31285030 | 0.90 | MAPK8 (0.44) | EGFRACVR1 | |
| SCHEMBL22950995 | 0.89 | ACVR1 (0.44) | EGFRACVR1PTK2FGFR3 | |
| SCHEMBL25001571 | 0.89 | EGFR (0.45) | EGFRPTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360102-A1 | PYRIMIDINE-4,6-DIAMINE DERIVATIVE, A PREPARATION METHOD THEREFOR, AND A PHARMACEUTICAL APPLICATION THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2024-10-31 | — | — | US | disclosed |
| EP-4382520-A1 | PYRIMIDINE-4,6-DIAMINE DERIVATIVE, A PREPARATION METHOD THEREFOR, AND A PHARMACEUTICAL APPLICATION THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2024-06-12 | — | — | EP | disclosed |
| US-20240051940-A1 | SULFONAMIDES WITH EGFR INHIBITION ACTIVITIES AND THEIR USE THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-02-15 | — | — | US | disclosed |
| US-20230131025-A1 | QUINOLYL PHOSPHINE OXIDE COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20230131025-A1 | QUINOLYL PHOSPHINE OXIDE COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| WO-2023011299-A1 | PYRIMIDINE-4,6-DIAMINE DERIVATIVE, A PREPARATION METHOD THEREFOR, AND A PHARMACEUTICAL APPLICATION THEREOF | 上海和誉生物医药科技有限公司 | 2023-02-09 | — | — | WO | disclosed |
| WO-2023011299-A1 | PYRIMIDINE-4,6-DIAMINE DERIVATIVE, A PREPARATION METHOD THEREFOR, AND A PHARMACEUTICAL APPLICATION THEREOF | 上海和誉生物医药科技有限公司 | 2023-02-09 | — | — | WO | disclosed |
| EP-4105207-A1 | QUINOLYL PHOSPHINE OXIDE COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | Betta Pharmaceuticals Co., Ltd (CN) | 2022-12-21 | — | — | EP | disclosed |
| WO-2021160087-A1 | QUINOLYL PHOSPHINE OXIDE COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | 贝达药业股份有限公司 | 2021-08-19 | — | — | WO | disclosed |
| WO-2021104441-A1 | POLYAROMATIC COMPOUND AS EGFR KINASE INHIBITOR | 江苏先声药业有限公司 | 2021-06-03 | — | — | WO | disclosed |
| WO-2021057882-A1 | EGFR INHIBITOR, COMPOSITION AND PREPARATION METHOD THEREFOR | 贝达药业股份有限公司 | 2021-04-01 | — | — | WO | disclosed |
| WO-2021018009-A1 | EGFR INHIBITOR, COMPOSITION, AND PREPARATION METHOD THEREFOR | 贝达药业股份有限公司 | 2021-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230131025-A1 | QUINOLYL PHOSPHINE OXIDE COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | EGFR, ABL1, ERBB2 | EGFR 1/4885ACVR1 2649/4885PTK2 298/4885 |
| US-20240051940-A1 | SULFONAMIDES WITH EGFR INHIBITION ACTIVITIES AND THEIR USE THEREOF | EGFR, ERBB2, ERBB4 | EGFR 1/4885ACVR1 4657/4885PTK2 648/4885 |
| US-20240360102-A1 | PYRIMIDINE-4,6-DIAMINE DERIVATIVE, A PREPARATION METHOD THEREFOR, AND A PHARMACEUTICAL APPLICATION THEREOF | WEE1, WEE2, EGFR | EGFR 3/4885ACVR1 3542/4885PTK2 1798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.